Keyphrases
Neovascular Age-related Macular Degeneration (nAMD)
100%
Neovascular AMD
100%
Anti-vascular Endothelial Growth Factor Therapy
100%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
100%
Poor Response
42%
Photodynamic Therapy
28%
Subretinal Fluid
28%
Ceiling Effect
28%
Non-response
28%
Committee Member
28%
Baseline Visual Acuity
28%
Secondary Response
28%
Tachyphylaxis
28%
Increased Dose
14%
MEDLINE
14%
Genetic Variation
14%
Genotype
14%
Visual Acuity
14%
Lesion Characteristics
14%
Acuity
14%
Withholding
14%
Partial Response
14%
Monotherapy
14%
Clinical Decision-making
14%
Cellular Mechanisms
14%
Visual Loss
14%
Alternative Therapy
14%
Lesion Types
14%
Confounding Factors
14%
Ophthalmologist
14%
Dose Rate
14%
Best Response
14%
Molecular Configuration
14%
Functional Response
14%
Advanced Stage
14%
As(V)
14%
Undertreatment
14%
Response to Treatment
14%
Ranibizumab
14%
Disease Activity
14%
Retreatment
14%
Morphological Criteria
14%
Risk Allele
14%
Clinical Factors
14%
Royal College
14%
Primary Response
14%
Retinal Thinning
14%
Unsuccessful Treatment
14%
Responder Status
14%
Genetic Potential
14%
Chronic Stage
14%
Non-clinical Factors
14%
Therapy Discontinuation
14%
Treatment Initiation
14%
Morphological Response
14%
Functional Criteria
14%
Functional Metrics
14%
Optimal Response
14%
Good Responders
14%
ETDRS
14%
Suboptimal Dosing
14%
Polypoidal Choroidal Vasculopathy
14%
Medicine and Dentistry
Vasculotropin
100%
Wet Macular Degeneration
50%
Visual Acuity
21%
Morphology
14%
Photochemotherapy
14%
Tachyphylaxis
14%
Base
7%
Allele
7%
Monotherapy
7%
Visual Impairment
7%
Clinical Decision Making
7%
Cellular Mechanism
7%
Ranibizumab
7%
Subretinal Fluid
7%
Retreatment
7%
Treatment Response
7%
Disease Activity
7%
Genetic Variation
7%
Diseases
7%
Treatment Outcome
7%
Neuroscience
Vascular Endothelial Growth Factor
100%
Age-Related Macular Degeneration
50%
Visual Acuity
21%
Decision-Making
7%
Individual Differences
7%
Ranibizumab
7%
Genetic Variation
7%